The therapeutic success of anti-CD19 chimeric antigen receptor (CAR)-T cells in some MM patients suggests that phenotypically clonal B cells may be clinically relevant therapeutic targets for some selected cases [48,49,50,51]. Here, CD19 is linked to Miyoshi myopathy.